
Dupixent: An injected biologic for moderate to severe eczema. It blocks two of the immune signals that drive the itch, and it is taken long term rather than as a course. Protopic: A non-steroid ointment for eczema, used where steroids are hardest to keep using: the face, the eyelids, and skin folds. It carries a boxed warning that twenty years of follow-up have not supported.


Choose for moderate to severe eczema that creams can't control, as a long-term treatment without blood tests.
Choose for eczema where steroids are hardest to keep using — face, eyelids, folds — or to prevent flares twice a week.
Can you take them together?
Protopic is often used on the face and eyelids while on Dupixent, where eczema can linger.
Compare uses by strength of evidence. Evidence level describes confidence in a benefit, not its size.












Blocks IL-4 and IL-13 signals: Binds their shared receptor to interrupt these messages. Calms type 2 inflammation: Reduces immune signaling that drives eczema. Eases eczema and itch: Inflamed skin and itch improve as signaling falls.
Dupilumab binds IL-4 receptor alpha, inhibiting IL-4 and IL-13 signaling. Diagram focuses on atopic dermatitis; it does not show every approved indication or all downstream effects.

Inhibits calcineurin: Blocks a switch that helps activate T cells. Reduces immune messengers: T cells release fewer inflammation-driving signals. Calms eczema and itch: Redness and irritation ease as inflammation settles.
The drug binds FKBP-12 and inhibits calcineurin, reducing T-cell cytokine transcription; the complete atopic-dermatitis mechanism is not known. It also has other cellular effects.
There is no titration. The number is fixed by age and weight; the only variable is how often you inject.
Loading dose: Adults start with two 300 mg injections the same day at two different spots — 600 mg total. That front-loading reaches a working level quickly.
Usual dose: 300 mg every two weeks for adults. Adolescents 12 and over who weigh about 60 kg or more use the same schedule.
Children and smaller adolescents: Dose is set by weight, and the youngest children inject every four weeks rather than every two. Go by the prescription.
Going up: There is nothing higher. If it is not working at sixteen weeks, the conversation is about a different treatment, not a bigger dose.
Total course: Open-ended. This is maintenance, not a course — people stay on it for years when it works.
When to Apply: A thin layer twice a day to the affected skin, rubbed in gently. It goes on the rash, not over clear skin. Keep moisturizer a couple of hours apart — layering one straight onto the other has not been studied.
How to Start: Twice a day until the patch clears, usually one to three weeks, then stop. Many people then move to maintenance — twice a week on the places that always flare, even when they look normal. That is well supported and makes flares less frequent.
If It Irritates: Burning or stinging for fifteen to thirty minutes after applying is very common in the first days and is not an allergy. It settles within about a week. Keeping the tube in the fridge, applying to dry rather than damp skin, and skipping alcohol early on all help.
If It's Not Working: Check it is going on twice a day — two to three weeks is a fair trial. Then the options are the higher strength if you are an adult on 0.03%, a short steroid course to break the flare, or a look at whether infection or a contact allergy is driving the rash.
Pick a day of the week and keep it. Take the pen or syringe out of the fridge 30 to 45 minutes ahead and let it warm to room temperature on its own — never in hot water, on a radiator, or in a microwave. A cold injection stings much more, and that one step explains most of the difference between people.
Inject into the front of the thigh or the abdomen, at least two inches from the navel. The upper arm works if someone else is injecting. Change the spot each time and avoid skin that is bruised, tender, scarred, or flaring. If the dose is two injections, give them one after the other in two different spots.
Give it as soon as you remember, as long as that is within about a week of the due day, then go back to your schedule. If longer than that, skip it and take the next on the usual day. Never double up to catch up. One missed injection does not undo months of treatment.
No routine blood tests are required — no liver, kidney, or blood count checks, which is a real advantage over the older systemic eczema drugs. Monitoring is a conversation about the skin, the itch, and the eyes.
Ask about the eyes at every visit. Conjunctivitis affects roughly one in ten people treated for eczema, more often with severe skin or eyelid involvement, and usually responds to lubricating drops or a short prescription course. Eye pain or changed vision goes to an eye doctor rather than being watched. Eosinophil counts rise in some people without causing anything, so a count taken for another reason should be read with that in mind.
Nothing builds up over the years, and there is no ceiling on how long you can stay on it. The recurring problem is insurance renewal, not safety.
No blood tests are needed. Blood levels are usually undetectable with the ointment and fall further as the barrier repairs — the opposite of the oral form used after transplants. Monitoring is a check at two to three weeks on whether the rash responded, then a plan for maintenance.
The boxed warning is the part to understand. It says long-term safety is not established, that rare cases of lymphoma and skin cancer were reported in people who used these drugs, and that continuous long-term use should be avoided. It was added in 2006, based mainly on animal studies using very high doses by mouth or injection, plus scattered case reports.
What has happened since matters. Large cohort studies, and a registry that followed treated children for a decade, have not found the rise in lymphoma the warning describes. Guidelines in the United States and Europe still recommend these drugs, including on the face and eyelids and as twice-weekly maintenance. The concern was theoretical, more than twenty years of use has not borne it out, and how long to continue is still a decision to make with a doctor.
Day-to-day monitoring is simple: keep skin checks routine, use sun protection on treated areas, and pause during a skin infection.
Approximate windows, not promises.
First few minutesThe injection: A sting for a few seconds, then redness or aching. Common early, and it settles with later doses.
First few minutesApplying it: A thin layer twice a day. Burning or stinging for a short while afterward is common and worst in the first week.
Weeks 1 to 2Itch lifts: Often within days, before anything shows in the mirror. The earliest and most reliable change.
Weeks 2 to 8Working: Sleep improves, scratching drops, and the skin looks calmer. Red or gritty eyes, if they happen, start here.
Weeks 12 to 16Judge it here: Trials measured their main result at sixteen weeks. Most responders reach their best skin here and a good number get close to clear; people only partly better at twelve often kept improving.
Weeks 12 to 24Sleep and daily life: These follow the itch, on a similar timeline, and trials measured them separately from the rash.
After 6 monthsThe face and neck: A stubborn pink patch appears here in a minority, usually after the rest of the skin has cleared. It is treatable and not a sign the drug has stopped working.
Days 1 to 7Adjusting: Burning is at its worst now. Itch often improves in the same week, which is what gets most people through.
Weeks 1 to 3Working: Redness and thickening settle and the burning has usually stopped. Most people reach their best result here.
MaintenanceKeeping flares apart: Once clear, twice-weekly use on the trouble spots lengthens the gaps between flares. Licensed, not an improvisation.
Sorted by what to do about them.
Cost decides access here more often than anything medical. Dupilumab is a biologic with no generic and no biosimilar in the United States, and the list price runs to tens of thousands of dollars a year. Almost nobody pays that, and almost everybody has to do the paperwork that brings it down.
Prior authorization is close to universal. Plans want a diagnosis, a record of how much of the body is affected, and evidence that prescription topicals were tried and could not hold the disease — usually a mid- or high-strength steroid, often a calcineurin inhibitor too. Some add phototherapy or an older systemic drug first. First-pass denials are common and appeals often succeed, so a denial is a step, not the end. Ask the prescribing office who handles appeals.
The manufacturer's copay program cuts the monthly cost sharply for people with commercial insurance, and a separate program covers people with no insurance. Copay cards cannot be used with Medicare, Medicaid, or other government plans, which is where the largest out-of-pocket gaps sit. Terms change every year, so a plan that refused last year is worth asking again.
Both strengths come as generics, which brought the price down a long way, though it still costs more than a generic steroid ointment. Prices vary widely between pharmacies and discount cards sometimes beat insurance, so check more than one.
Prior authorization is still common, usually asking that a topical steroid was tried first. Tube size is the practical variable: twice-daily use means a small tube treating a child's face lasts far longer than the same tube on two hands.
Itch often improves within two weeks. The skin takes longer — sixteen weeks is the fair point to judge.
It stings for a few seconds. Letting it reach room temperature first makes the biggest difference.
Roughly one in ten get red or gritty eyes, more often with severe eczema or eyelid involvement. Most settle with drops.
No routine tests, which is unusual for a drug of this kind.
Some people do, and some keep a good stretch. Eczema usually returns eventually, and restarting normally works.
Yes. Most people need far less, but flares still get topical treatment, and moisturizer continues indefinitely.
Yes, and it is printed on the label — long-term safety is not established, and rare cases were reported. Studies following large groups for years have not found the increased risk. A caution, not a demonstrated harm.
It acts on nerve endings in inflamed skin as well as on immune cells. Burning is worst in the first few days and gone within a week as the rash heals.
Yes — eyelid eczema is one of the main reasons it gets prescribed. Keep it off the eye itself and the lid margin.
Alcohol flushing is a known effect while using it. Harmless, and it stops when the treatment does.
The label asks for the shortest suitable use and for breaks. Twice-weekly maintenance on trouble spots is licensed and widely used. Make that decision with a doctor rather than leaving a prescription running.
No. Blood levels are usually undetectable with the ointment. The tablets are a different treatment entirely.